Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
The purpose of this research study is to determine if letrozole is effective at controlling
the growth or spread of estrogen and/or progesterone receptor positive uterine
leiomyosarcoma. This drug has been used in research studies for other cancers and is
currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone
levels in the body, it may be helpful to control tumors that express hormone receptors (
ER/PR).
- Participants will take letrozole orally once a day. During the research study the
following tests and procedures will be performed:
- Visit 1 (Day 1): physical examination, vital signs and blood work
- Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan
- Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan
- Participants will remain on the study drug as long as they do not have any serious sife
effect and their disease does not get worse
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
